PTEN as a Unique Promising Therapeutic Target for Occupational Asthma

REFERENCES

• S. Meredith, and H. Nordman. 1996. Occupational asthma: Measures and frequency from four countries. Thorax 51 (4):435–440.
   PubMedGoogle Scholar
• D.M. Mannino. 2000. How much asthma is occupationally related?. Occup. Med. 15 (2):359–368.
   PubMedGoogle Scholar
• P.D. Blanc, and K. Toren. 1999. How much asthma can be attributed to occupational factors?. Am. J. Med. 107 (6):580–587.
   PubMedGoogle Scholar
• J. Balmes, M. Becklake, P. Blanc, P. Henneberger, K. Kreiss, C.E. Mapp, D. Milton, D. Schwartz, K. Toren, and G. Viegi. 2003. American Thoracic Society statement: Occupational contribution to the burden of airway disease. Am. J. Respir. Crit. Care Med. 167 (5):787–797.
   PubMedGoogle Scholar
• C.E. Mapp, P. Boschetto, P. Maestrelli, and L.M. Fabbri. 2005. Occupational asthma. Am. J. Respir. Crit. Care Med. 172 (3):280–305.
   PubMedGoogle Scholar
• C.E. Mapp, P. Boschetto, E. Zocca, G.F. Milani, F. Pivirotto, V. Tegazzin, and L.M. Fabbri. 1987. Pathogenesis of late asthmatic reactions induced by exposure to isocyanates. Bull. Eur. Physiopathol. Respir. 23 (6):583–586.
   PubMedGoogle Scholar
• M. Saetta, P. Maestrelli, G. Turato, C.E. Mapp, G. Milani, F. Pivirotto, L.M. Fabbri, and A. Di Stefano. 1995. Airway wall remodeling after cessation of exposure to isocyanates in sensitized asthmatic subjects. Am. J. Respir. Crit. Care Med. 151 (2 Pt 1):489–494.
   PubMedGoogle Scholar
• G.F. Del Prete, M. DeCarli, M.M. D'Elios, P. Maestrelli, M. Ricci, L. Fabbri, and S. Romagnani. 1993. Allergen exposure induces the activation of allergen-specific Th2 cells in the airway mucosa of patients with allergic respiratory disorders. Eur. J. Immunol. 23 (7):1445–1449.
   PubMedGoogle Scholar
• S. Finotto, L.M. Fabbri, V. Rado, C.E. Mapp, and P. Maestrelli. 1991. Increase in numbers of CD8 positive lymphocytes and eosinophils in peripheral blood of subjects with late asthmatic reactions induced by toluene diisocyanate. Br. J. Ind. Med. 48 (2):116–121.
   PubMedGoogle Scholar
• D. Gautrin, A.J. Newman-Taylor, H. Nordman, and J.L. Malo. 2003. Controversies in epidemiology of occupational asthma. Eur. Respir. J. 22 (3):551–559.
   PubMedGoogle Scholar
• P. Maestrelli, G.F. Del Prete, M. De Carli, M.M. D'Elios, M. Saetta, A. Di Stefano, C.E. Mapp, S. Romagnani, and L.M. Fabbri. 1994. CD8 T-cell clones producing interleukin-5 and interferon-gamma in bronchial mucosa of patients with asthma induced by toluene diisocyanate. Scand. J. Work Environ. Health. 20 (5):376–381.
   PubMedGoogle Scholar
• C.E. Mapp, M. Saetta, P. Maestrelli, A.D. Stefano, P. Chitano, P. Boschetto, A. Ciaccia, and L.M. Fabbri. 1994. Mechanisms and pathology of occupational asthma. Eur. Respir. J. 7 (9):544–554.
   PubMedGoogle Scholar
• M. Raulf-Heimsoth, and X. Baur. 1998. Pathomechanisms and pathophysiology of Isocyanate-induced diseases-summary of present knowledge. Am. J. Ind. Med. 34 (2):137–143.
   Google Scholar
• R.D. Tee, P. Cullinan, J. Welch, P.S. Burge, and A.J. Newman-Taylor. 1998. Specific IgE to isocyanates: A useful diagnostic role in occupational asthma. J. Allergy Clin. Immunol. 101 (5):709–715.
   PubMedGoogle Scholar
• M. Saetta, A. Di Stefano, P. Maestrelli, N. De Marzo, G.F. Milani, F. Pivirotto, C.E. Mapp, and L.M. Fabbri. 1992. Airway mucosal inflammation in occupational asthma induced by toluene diisocyanate. Am. Rev. Respir. Dis. 145 (1):160–168.
   PubMedGoogle Scholar
• A.J. Frew, H. Chan, S. Lam, and M. Chan-Yeung. 1995. Bronchial inflammation in occupational asthma due to western red cedar. Am. J. Respir. Crit. Care Med. 151 (2 Pt 1):340–344.
   PubMedGoogle Scholar
• P. Maestrelli, A. Di Stefano, P. Occari, G. Turato, G.F. Milani, F. Pivirotto, C.E. Mapp, L.M. Fabbri, and M. Saetta. 1995. Cytokines in the airway mucosa of subjects with asthma induced by toluene diisocyanate. Am. J. Respir. Crit. Care Med. 151 (3 Pt 1):607–612.
   PubMedGoogle Scholar
• P. Maestrelli, P. Occari, G. Turato, S.A. Papiris, A. Di Stefano, C.E. Mapp, G.F. Milani, L.M. Fabbri, and M. Saetta. 1997. Expression of interleukin (IL)-4 and IL-5 proteins in asthma induced by toluene diisocyanate (TDI). Clin. Exp. Allergy. 27 (11):1292–1298.
   PubMedGoogle Scholar
• K.M. Yamada, and M. Araki. 2001. Tumor suppressor PTEN: Modulator of cell signaling, growth, migration and apoptosis. J. Cell Sci. 114 (Pt 113):2375–2382.
   PubMedGoogle Scholar
• L.C. Cantley, and B.G. Neel. 1999. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci. U S A 96 (8):4240–4245.
   PubMedGoogle Scholar
• Y.G. Kwak, C.H. Song, H.K. Yi, P.H. Hwang, J.S. Kim, K.S. Lee, and Y.C. Lee. 2003. Involvement of PTEN in airway hyperresponsiveness and inflammation in bronchial asthma. J. Clin. Invest. 111 (7):1083–1092.
   PubMedGoogle Scholar
• S.R. Kim, K.S. Lee, S.J. Park, K.H. Min, K.Y. Lee, Y.H. Choe, Y.R. Lee, J.S. Kim, S.J. Hong, and Y.C. Lee. 2007. PTEN down-regulates IL-17 expression in a murine model of toluene diisocyanate-induced airway disease. J. Immunol. 179 (10):6820–6829.
   PubMedGoogle Scholar
• C.A. Redlich, and M.H. Karol. 2002. Diisocyanate asthma: Clinical aspects and immunopathogenesis. Int. Immunopharmacol. 2 (2–3):213–224.
   PubMedGoogle Scholar
• X. Baur. 1996. Occupational asthma due to isocyanates. Lung 174 (1):23–30.
   PubMedGoogle Scholar
• J.A. Bernstein. 1996. Overview of diisocyanate occupational asthma. Toxicology 111 (1–3):181–189.
   PubMedGoogle Scholar
• M.G. Ott, J.E. Klees, and S.L. Poche. 2000. Respiratory health surveillance in a toluene diisocyanate production unit, 1967–97: Clinical observations and lung function analyses. Occup. Environ. Med. 57 (1):43–52.
   PubMedGoogle Scholar
• I.L. Bernstein, D.I. Bernstein, M. Chan-Yeung, and J.L. Malo. Definition and classification of asthmaAsthma in the WorkplaceI.L. Bernstein, M. Chan-Yeung, J.L. Malo, and D.I. Bernstein. Marcel Dekker, New York, 1999 1–3.
   Google Scholar
• M. Chan-Yeung. 1995. American College of Chest Physicians. Assessment of asthma in the workplace: ACCP consensus statement. Chest 108 (4):1084–1117.
   PubMedGoogle Scholar
• C.A. Redlich, H. Cain, and A.V. Wisnewski. 1999. The immunology and prevention of isocyanate asthma: A model for low molecular weight asthma. Semin. Respir. Crit. Care Med. 20 (6):591–599.
   Google Scholar
• G. Friedman-Jimenez, W.S. Beckett, J. Szeinuk, and E.L. Petsonk. 2000. Clinical evaluation, management, and prevention of work-related asthma. Am. J. Ind. Med. 37 (1):121–141.
   PubMedGoogle Scholar
• C.A. Redlich, R.J. Homer, B.R. Smith, J.A. Wirth, and M.R. Cullen. 1996. Immunologic responses to isocyanates in sensitized asthmatic subjects. Chest 109 (3 Suppl):6S–8S.
   PubMedGoogle Scholar
• B. Perrin, A. Cartier, H. Ghezzo, L. Grammer, K. Harris, H. Chan, M. Chan-Yeung, and J.L. Malo. 1991. Reassessment of the temporal patterns of bronchial obstruction after exposure to occupational sensitizing agents. J. Allergy Clin. Immunol. 87 (3):630–639.
   PubMedGoogle Scholar
• D.I. Bernstein, and A. Jolly. 1999. Current diagnostic methods for diisocyanate induced occupational asthma. Am. J. Ind. Med. 36 (4):459–468.
   PubMed Web of Science ®Google Scholar
• C. Mapp, P. Boschetto, D. Miotto, E. De Rosa, and L.M. Fabbri. 1999. Mechanisms of occupational asthma. Ann. Allergy Asthma Immunol. 83 (6 Pt 2):645–664.
   PubMedGoogle Scholar
• H. Scheerens, T.L. Buckley, T. Muis, H. Van Loveren, and F.P. Nijkamp. 1996. The involvement of sensory neuropeptides in toluene diisocyanate-induced tracheal hyperreactivity in the mouse airways. Br. J. Pharmacol. 119 (8):1665–1671.
   PubMedGoogle Scholar
• A.M. Bentley, S.R. Durham, and A.B. Kay. 1994. Comparison of the immunopathology of extrinsic, intrinsic and occupational asthma. J. Investig. Allergol. Clin. Immunol. 4 (5):222–232.
   PubMedGoogle Scholar
• A.M. Bentley, P. Maestrelli, M. Saetta, L.M. Fabbri, D.S. Robinson, B.L. Bradley, P.K. Jeffery, S.R. Durham, and A.B. Kay. 1992. Activated T-lymphocytes and eosinophils in the bronchial mucosa in isocyanate-induced asthma. J. Allergy Clin. Immunol. 89 (4):821–829.
   PubMedGoogle Scholar
• H.S. Park, S.C. Hwang, D.H. Nahm, and H.E. Yim. 1998. Immunohistochemical characterization of the cellular infiltrate in airway mucosa of toluene diisocyanate (TDI)-induced asthma: Comparison with allergic asthma. J. Korean Med. Sci. 13 (1):21–26.
   PubMedGoogle Scholar
• V.L. Ott, J.C. Cambier, J. Kappler, P. Marrack, and B.J. Swanson. 2003. Mast cell dependent migration of effector CD8+ T cells through production of leukotriene B4. Nat. Immunol. 4 (10):974–981.
   PubMedGoogle Scholar
• E. Zocca, L.M. Fabbri, P. Boschetto, M. Plebani, M. Masiero, G.F. Milani, F. Pivirotto, and C.E. Mapp. 1990. Leukotriene B4 and late asthmatic reactions induced by toluene diisocyanate. J. Appl. Physiol. 68 (4):1576–1580.
   PubMedGoogle Scholar
• C.A. Herrick, J. Das, L. Xu, A.V. Wisnewski, C.A. Redlich, and K. Bottomly. 2003. Differential roles for CD4 and CD8 T cells after diisocyanate sensitization: Genetic control of TH2-induced lung inflammations. J. Allergy Clin. Immunol. 111 (5):1087–1094.
   PubMedGoogle Scholar
• J.M. Matheson, V.J. Johnson, and M.I. Luster. 2005. Immune mediators in a murine model for occupational asthma: Studies with toluene diisocyanate. Toxicol. Sci. 84 (1):99–109.
   PubMedGoogle Scholar
• J.M. Matheson, V.J. Johnson, V. Vallyathan, and M.I. Luster. 2005. Exposure and immunological determinants in a murine model for toluene diisocyanate (TDI) asthma. Toxicol. Sci. 84 (1):88–98.
   PubMedGoogle Scholar
• K. Kouadio, K.C. Zheng, M.K. Tuekpe, H. Todoriki, and M. Ariizumi. 2005. Airway inflammatory and immunological events in a rat model exposed to toluene diisocyanate. Food Chem. Toxicol. 43 (8):1281–1288.
   PubMedGoogle Scholar
• Z.L. Lummus, R. Alam, J.A. Bernstein, and D.I. Bernstein. 1998. Diisocyanate antigen-enhanced production of monocyte chemoattractant protein-1, IL-8, and tumor necrosis factor-alpha by peripheral mononuclear cells of workers with occupational asthma. J. Allergy Clin. Immunol. 102 (2):265–274.
   PubMedGoogle Scholar
• L.M. Fabbri, P. Boschetto, E. Zocca, G. Milani, F. Pivirotto, M. Plebani, A. Burlina, B. Licata, and C.E. Mapp. 1987. Bronchoalveolar neutrophilia during late asthmatic reactions induced by toluene diisocyanate. Am. Rev. Respir. Dis. 136 (1):36–42.
   PubMedGoogle Scholar
• H. Park, K. Jung, H. Kim, D. Nahm, and K. Kang. 1999. Neutrophil activation following TDI bronchial challenges to the airway secretion from subjects with TDI-induced asthma. Clin. Exp. Allergy 29 (10):1395–1401.
   PubMedGoogle Scholar
• J.O. Lee, H. Yang, M.M. Georgescu, A. Di Cristofano, T. Maehama, Y. Shi, J.E. Dixon, P. Pandolfi, and N.P. Pavletich. 1999. Crystal structure of the PTEN tumor suppressor: Implications for its phosphoinositide phosphatase activity and membrane association. Cell 99 (3):323–334.
   PubMedGoogle Scholar
• F. Vazquez, and W.R. Sellers. 2000. The PTEN tumor suppressor protein: An antagonist of phosphoinositide 3-kinase signaling. Biochim. Biophys. Acta. 1470 (1):M21–M35.
   Google Scholar
• T. Maehama, G.S. Taylor, and J.E. Dixon. 2001. PTEN and myotubularin: Novel phosphoinositide phosphatases. Annu. Rev. Biochem. 70:247–279.
   PubMed Web of Science ®Google Scholar
• S.M. Walker, N.R. Leslie, N.M. Perera, I.H. Batty, and C.P. Downes. 2004. The tumour-suppressor function of PTEN requires an N-terminal lipid-binding motif. Biochem. J. 379 (Pt 2):301–307.
   PubMedGoogle Scholar
• M.A. Lemmon, and K.M. Ferguson. 2000. Signal-dependent membrane targeting by pleckstrin homology (PH) domains. Biochem. J. 350 (Pt 1):1–18.
   PubMedGoogle Scholar
• J. Li, C. Yen, D. Liaw, K. Podsypanina, S. Bose, S.I. Wang, J. Puc, C. Miliaresis, L. Rodgers, R. McCombie, S.H. Bigner, B.C. Giovanella, M. Ittmann, B. Tycko, H. Hibshoosh, M.H. Wigler, and R. Parsons. 1997. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275 (5308):1943–1947.
   PubMed Web of Science ®Google Scholar
• A. Toker, and L.C. Cantley. 1997. Signalling through the lipid products of phosphoinositide-3-OH kinase. Nature 387 (6634):673–676.
   PubMedGoogle Scholar
• M. Tamura, J. Gu, K. Matsumoto, S. Aota, R. Parsons, and K.M. Yamada. 1998. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 280 (5369):1614–1617.
   PubMedGoogle Scholar
• J. Gu, M. Tamura, R. Pankov, E.H. Danen, T. Takino, K. Matsumoto, and K.M. Yamada. 1999. Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. J. Cell Biol. 146 (2):389–403.
   PubMedGoogle Scholar
• L. Mahimainathan, and G.G. Choudhury. 2004. Inactivation of platelet-derived growth factor receptor by the tumor suppressor PTEN provides a novel mechanism of action of the phosphatase. J. Biol. Chem. 279 (15):15258–15268.
   PubMedGoogle Scholar
• D. Stokoe. 2001. Pten. Curr. Biol. 11 (13):R502.
   Google Scholar
• D. Liaw, D.J. Marsh, J. Li, P.L. Dahia, S.I. Wang, Z. Zheng, S. Bose, K.M. Call, H.C. Tsou, M. Peacocke, C. Eng, and R. Parsons. 1997. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet. 16 (1):64–67.
   PubMedGoogle Scholar
• M. Groszer, R. Erickson, D.D. Scripture-Adams, J.D. Dougherty, J. Le Belle, J.A. Zack, D.H. Geschwind, X. Liu, H.I. Kornblum, and H. Wu. 2006. PTEN negatively regulates neural stem cell self-renewal by modulating G0-G1 cell cycle entry. Proc. Natl. Acad. Sci. U.S.A. 103 (1):111–116.
   PubMedGoogle Scholar
• S. Wang, A.J. Garcia, M. Wu, D.A. Lawson, O.N. Witte, and H. Wu. 2006. Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc. Natl. Acad. Sci. U.S.A. 103 (5):1480–1485.
   PubMedGoogle Scholar
• O.H. Yilmaz, R. Valdez, B.K. Theisen, W. Guo, D.O. Ferguson, H. Wu, and S.J. Morrison. 2006. Pten dependence distinguishes haematopoietic stem cells from leukaemiainitiating cells. Nature. 441 (7092):475–482.
   PubMedGoogle Scholar
• T. Kimura, A. Suzuki, Y. Fujita, K. Yomogida, H. Lomeli, N. Asada, M. Ikeuchi, A. Nagy, T.W. Mak, and T. Nakano. 2003. Conditional loss of PTEN leads to testicular teratoma and enhances embryonic germ cell production. Development 130 (8):1691–1700.
   PubMedGoogle Scholar
• T.J. Hagenbeek, M. Naspetti, F. Malergue, F. Garçon, J.A. Nunès, K.B. Cleutjens, J. Trapman, P. Krimpenfort, and H. Spits. 2004. The loss of PTEN allows TCR alphabeta lineage thymocytes to bypass IL-7 and Pre-TCR-mediated signaling. J. Exp. Med. 200 (7):883–894.
   PubMedGoogle Scholar
• A. Suzuki, T. Kaisho, M. Ohishi, M. Tsukio-Yamaguchi, T. Tsubata, P.A. Koni, T. Sasaki, T.W. Mak, and T. Nakano. 2003. Critical roles of Pten in B cell homeostasis and immunoglobulin class switch recombination. J. Exp. Med. 197 (5):657–667.
   PubMedGoogle Scholar
• K. Hamada, T. Sasaki, P.A. Koni, M. Natsui, H. Kishimoto, J. Sasaki, N. Yajima, Y. Horie, G. Hasegawa, M. Naito, J. Miyazaki, T. Suda, H. Itoh, K. Nakao, T.W. Mak, T. Nakano, and A. Suzuki. 2005. The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis. Genes Dev. 19 (17):2054–2065.
   PubMedGoogle Scholar
• S. Yanagi, H. Kishimoto, K. Kawahara, T. Sasaki, M. Sasaki, M. Nishio, N. Yajima, K. Hamada, Y. Horie, H. Kubo, J.A. Whitsett, T.W. Mak, T. Nakano, M. Nakazato, and A. Suzuki. 2007. PTEN controls lung morphogenesis, bronchoalveolar stem cells, and onset of lung adenocarcinomas in mice. J. Clin. Invest. 117 (10):2929–2940.
   PubMedGoogle Scholar
• G.P. Anderson, and S. Bozinovski. 2003. Acquired somatic mutations in the molecular pathogenesis of COPD. Trends Pharmacol. Sci. 24 (2):71–76.
   PubMedGoogle Scholar
• T. Pap, J.K. Franz, K.M. Hummel, E. Jeisy, R. Gay, and S. Gay. 2000. Activation of synovial fibroblasts in rheumatoid arthritis: Lack of expression of the tumour suppressor PTEN at sites of invasive growth and destruction. Arthritis Res. 2 (1):59–64.
   PubMedGoogle Scholar
• E.S. White, V.J. Thannickal, S.L. Carskadon, E.G. Dickie, D.L. Livant, S. Markwart, G.B. Toews, and D.A. Arenberg. 2003. Integrin alpha4beta1 regulates migration across basement membranes by lung fibroblasts: A role for phosphatase and tensin homologue deleted on chromosome 10. Am. J. Respir. Crit. Care Med. 168 (4):436–442.
   PubMedGoogle Scholar
• K. Ito, G. Caramori, and I.M. Adcock. 2007. Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory disease. J. Pharmacol. Exp. Ther. 321 (1):1–8.
   PubMedGoogle Scholar
• M. Kawaguchi, M. Adachi, N. Oda, F. Kokubu, and S.K. Huang. 2004. IL-17 cytokine family. J. Allergy Clin. Immunol. 114 (6):1265–1273.
   PubMedGoogle Scholar
• S. Ivanov, S. Bozinovski, A. Bossios, H. Valadi, R. Vlahos, C. Malmhall, M. Sjostrand, J.K. Kolls, G.P. Anderson, and A. Linden. 2007. Functional relevance of the IL-23-IL-17 axis in lungs in vivo. Am. J. Respir. Cell Mol. Biol. 36 (4):442–451.
   PubMedGoogle Scholar
• A. Linden, M. Laan, and G.P. Anderson. 2005. Neutrophils, interleukin-17A and lung disease. Eur. Respir. J. 25 (1):159–172.
   PubMedGoogle Scholar
• B.P. Kota, T.H. Huang, and B.D. Roufogalis. 2005. An overview on biological mechanisms of PPARs. Pharmacol. Res. 51 (2):85–94.
   PubMedGoogle Scholar
• P. Tontonoz, E. Hu, and B.M. Spiegelman. 1994. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 79 (7):1147–1156.
   PubMedGoogle Scholar
• G. Chinetti, S. Griglio, M. Antonucci, I.P. Torra, P. Delerive, Z. Majd, J. C. Fruchart, J. Chapman, J. Najib, and B. Staels. 1998. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J. Biol. Chem. 273 (40):25573–25580.
   PubMedGoogle Scholar
• L. Gelman, J.C. Fruchart, and J. Auwerx. 1999. An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer. Cell Mol. Life Sci. 55 (6–7):932–943.
   PubMedGoogle Scholar
• C. Jiang, A.T. Ting, and B. Seed. 1998. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 391 (6662):82–86.
   PubMedGoogle Scholar
• L. Patel, I. Pass, P. Coxon, C.P. Downes, S.A. Smith, and C.H. Macphee. 2001. Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. Curr. Biol. 11 (10):764–768.
   PubMedGoogle Scholar
• K.S. Lee, S.J. Park, P.H. Hwang, H.K. Yi, C.H. Song, O.H. Chai, J.S. Kim, M.K. Lee, and Y.C. Lee. 2005. PPAR-gamma modulates allergic inflammation through up-regulation of PTEN. FASEB J. 19 (8):1033–1035.
   PubMedGoogle Scholar
• S.Y. Lee, E.J. Kang, G.Y. Hur, K.H. Jung, H.C. Jung, S.Y. Lee, J.H. Kim, C. Shin, K.H. In, K.H. Kang, S.H. Yoo, and J.J. Shim. 2006. Peroxisome proliferator-activated receptor-gamma inhibits cigarette smoke solution-induced mucin production in human airway epithelial (NCI-H292) cells. Am J Physiol Lung Cell Mol Physiol. 291 (1):L84–90.
   Google Scholar
• S. Ghosh, and M. Karin. 2002. Missing pieces in the NF-kappaB puzzle. Cell 109:S81–96.
   PubMed Web of Science ®Google Scholar
• P.J. Barnes, and M. Karin. 1997. Nuclear factor-κB - a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 336 (15):1066–1071.
   PubMed Web of Science ®Google Scholar
• X. Dolcet, D. Llobet, J. Pallares, and X. Matias-Guiu. 2005. NF-kB in development and progression of human cancer. Virchows Arch. 446 (5):475–482.
   PubMedGoogle Scholar
• P.J. Barnes, and I.M. Adcock. 1997. NF-kappa B: A pivotal role in asthma and a new target for therapy. Trends Pharmacol Sci. 18 (2):46–50.
   PubMedGoogle Scholar
• S.W. Han, and J. Roman. 2006. Fibronectin induces cell proliferation and inhibits apoptosis in human bronchial epithelial cells: Pro-oncogenic effects mediated by PI3-kinase and NF-kappa B. Oncogene 25 (31):4341–4349.
   PubMedGoogle Scholar
• M. Vinciguerra, C. Veyrat-Durebex, M.A. Moukil, L. Rubbia-Brandt, F. Rohner-Jeanrenaud, and M. Foti. 2008. PTEN down-regulation by unsaturated fatty acids triggers hepatic steatosis via an NF-kappaBp65/mTOR-dependent mechanism. Gastroenterology 134 (1):268–280.
   PubMedGoogle Scholar
• D. Xia, H. Srinivas, Y.H. Ahn, G. Sethi, X. Sheng, W.K. Yung, Q. Xia, P.J. Chiao, H. Kim, P.H. Brown, I.I. Wistuba, B.B. Aggarwal, and J.M. Kurie. 2007. Mitogen-activated protein kinase kinase-4 promotes cell survival by decreasing PTEN expression through an NF kappa B-dependent pathway. J. Biol. Chem. 282 (6):3507–3519.
   PubMedGoogle Scholar
• J. Bousquet, P.K. Jeffery, W.W. Busse, M. Johnson, and A.M. Vignola. 2000. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am. J. Respir. Crit. Care Med. 161 (5):1720–1745.
   PubMedGoogle Scholar
• H.F. Dvorak, L.F. Brown, M. Detmar, and A.M. Dvorak. 1995. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146 (5):1029–1039.
   PubMed Web of Science ®Google Scholar
• Y.C. Lee, Y.G. Kwak, and C.H. Song. 2002. Contribution of vascular endothelial growth factor to airway hyper-responsiveness and inflammation in a murine model of toluene diisocyanate-induced asthma. J. Immunol. 168 (7):3595–3600.
   PubMedGoogle Scholar
• C.G. Lee, H. Link, P. Baluk, R.J. Homer, S. Chapoval, V. Bhandari, M.J. Kang, L. Cohn, Y.K. Kim, D.M. McDonald, and J.A. Elias. 2004. Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung. Nat. Med. 10 (10):1095–1103.
   PubMedGoogle Scholar
• K.S. Lee, S.R. Kim, H.S. Park, G.Y. Jin, and Y.C. Lee. 2004. Cysteinyl leukotriene receptor antagonist regulates vascular permeability by reducing VEGF expression. J. Allergy Clin. Immunol. 114 (5):1093–1099.
   PubMedGoogle Scholar
• Y.C. Lee, and H.K. Lee. 2001. Vascular endothelial growth factor in patients with acute asthma. J. Allergy Clin. Immunol. 107 (6):1106–1108.
   PubMedGoogle Scholar
• G.L. Semenza. 2001. Hypoxia-inducible factor 1: Control of oxygen homeostasis in health and disease. Pediatr. Res. 49 (5):614–617.
   PubMedGoogle Scholar
• G.L. Wang, and G.L. Semenza. 1995. Purification and characterization of hypoxia-inducible factor 1. J. Biol. Chem. 270 (3):1230–1237.
   PubMedGoogle Scholar
• W.G. KaelinJr.. 2002. How oxygen makes its presence felt. Genes Dev. 16 (12):1441–1445.
   PubMedGoogle Scholar
• D. Feldser, F. Agani, N.V. Iyer, B. Pak, G. Ferreira, and G.L. Semenza. 1999. Reciprocal positive regulation of hypoxia-inducible factor 1α and insulin-like factor 2. Cancer Res. 59 (16):3915–3918.
   PubMedGoogle Scholar
• H. Zhong, K. Chiles, D. Feldser, E. Laughner, C. Hanrahan, M.M. Georgescu, J.W. Simons, and G.L. Semenza. 2000. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics. Cancer Res. 60 (6):1541–1545.
   PubMed Web of Science ®Google Scholar
• W. Zundel, C. Schindler, D. Haas-Kogan, A. Koong, F. Kaper, E. Chen, A.R. Gottschalk, H.E. Ryan, R.S. Johnson, A.B. Jefferson, D. Stokoe, and A.J. Giaccia. 2000. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 14 (4):391–396.
   PubMed Web of Science ®Google Scholar
• B.H. Jiang, G. Jiang, J.Z. Zheng, Z. Lu, T. Hunter, and P.K. Vogt. 2001. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ. 12 (7):363–369.
   PubMedGoogle Scholar
• B.H. Jiang, J.Z. Zheng, M. Aoki, and P.K. Vogt. 2000. Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 97 (4):1749–1753.
   PubMedGoogle Scholar
• H.D. Skinner, J.Z. Zheng, J. Fang, F. Agani, and B.H. Jiang. 2004. Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1alpha, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling. J. Biol. Chem. 279 (44):45643–45651.
   PubMedGoogle Scholar
• K.S. Lee, S.R. Kim, S.J. Park, H.K. Lee, H.S. Park, K.H. Min, S.M. Jin, and Y.C. Lee. 2006. Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) reduces vascular endothelial growth factor expression in allergen-induced airway inflammation. Mol. Pharmacol. 69 (6):1829–1839.
   PubMedGoogle Scholar
• J.H. Choi, Y.J. Suh, S.K. Lee, C.H. Suh, D.H. Nahm, and H.S. Park. 2004. Acute and chronic changes of vascular endothelial growth factor (VEGF) in induced sputum of toluene diisocyanate (TDI)-induced asthma patients. J. Korean Med. Sci. 19 (3):359–363.
   PubMedGoogle Scholar
• Y.M. Ye, Y.M. Kang, S.H. Kim, C.W. Kim, H.R. Kim, C.S. Hong, C.S. Park, H.M. Kim, D.H. Nahm, and H.S. Park. 2006. Relationship between neurokinin 2 receptor gene polymorphisms and serum vascular endothelial growth factor levels in patients with toluene diisocyanate-induced asthma. Clin. Exp. Allergy 36 (9):1153–1160.
   PubMedGoogle Scholar
• H.J. Peng, S.X. Cai, H.J. Zhao, W.J. Li, and W.C. Tong. 2008. Toluene diisocyanate increases vascular endothelial growth factor expression in human bronchial epithelial cells. J. South Med. Univ. 28 (2):209–212.
   Google Scholar
• H. Nagase. 1997. Activation mechanisms of matrix metalloproteinases. Biol. Chem. 378 (3–4):151–160.
   PubMed Web of Science ®Google Scholar
• H. Birkedal-Hansen. 1995. Proteolytic remodeling of extracellular matrix. Curr. Opin. Cell Biol. 7 (5):728–735.
   PubMedGoogle Scholar
• S. Okada, H. Kita, T.J. George, G.J. Gleich, and K.M. Leiferman. 1997. Migration of eosinophils through basement membrane components in vitro: Role of matrix metalloproteinase-9. Am. J. Respir. Cell Mol. Biol. 17 (4):519–528.
   PubMedGoogle Scholar
• A.M. Vignola, L. Riccobono, A. Mirabella, M. Profita, P. Chanez, V. Bellia, G. Mautino, P. D'accardi, J. Bousquet, and G. Bonsignore. 1998. Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis. Am. J. Respir. Crit. Care Med. 158 (6):1945–1950.
   PubMedGoogle Scholar
• M. Hoshino, M. Takahashi, Y. Takai, and J. Sim. 1999. Inhaled corticosteroids decrease subepithelial collagen deposition by modulation of the balance between matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 expression in asthma. J. Allergy Clin. Immunol. 104 (2 Pt 1):356–363.
   PubMedGoogle Scholar
• Y.C. Lee, C.H. Song, H.B. Lee, J.L. Oh, Y.K. Rhee, H.S. Park, and G.Y. Koh. 2001. A murine model of toluene diisocyanate-induced asthma can be treated with matrix metalloproteinase inhibitor. J. Allergy Clin. Immunol. 108 (6):1021–1026.
   PubMedGoogle Scholar
• K.S. Lee, S.M. Jin, S.S. Kim, and Y.C. Lee. 2004. Doxycycline reduces airway inflammation and hyperresponsiveness in a murine model of toluene diisocyanate-induced asthma. J. Allergy Clin. Immunol. 113 (5):902–909.
   PubMedGoogle Scholar
• H.S. Park, H.A. Kim, J.W. Jung, Y.K. Kim, S.K. Lee, S.S. Kim, and D.H. Nahm. 2003. Metalloproteinase-9 is increased after toluene diisocyanate exposure in the induced sputum from patients with toluene diisocyanate-induced asthma. Clin. Exp. Allergy 33 (1):113–118.
   PubMedGoogle Scholar
• G. Woerly, K. Honda, M. Loyens, J.P. Papin, J. Auwerx, B. Staels, M. Capron, and D. Dombrowicz. 2003. Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation. J. Exp. Med. 198 (3):411–421.
   PubMedGoogle Scholar
• K. Honda, P. Marquillies, M. Capron, and D. Dombrowicz. 2004. Peroxisome proliferator-activated receptor gamma is expressed in airways and inhibits features of airway remodeling in a mouse asthma model. J. Allergy Clin. Immunol. 113 (5):882–888.
   PubMedGoogle Scholar
• K.S. Lee, S.J. Park, S.R. Kim, K.H. Min, S.M. Jin, H.K. Lee, and Y.C. Lee. 2006. Modulation of airway remodeling and airway inflammation by peroxisome proliferator-activated receptor gamma in a murine model of toluene diisocyanate-induced asthma. J. Immunol. 177 (8):5248–5257.
   PubMedGoogle Scholar
• P. Boschetto, L.M. Fabbri, E. Zocca, G. Milani, F. Pivirotto, A. Dal Vecchio, M. Plebani, and C.E. Mapp. 1987. Prednisone inhibits late asthmatic reactions and airway inflammation induced by toluene diisocyanate in sensitized subjects. J. Allergy Clin. Immunol. 80 (3 Pt 1):261–267.
   PubMedGoogle Scholar
• S. Montefort, and S.T. Holgate. 1991. Adhesion molecules and their role in inflammation. Respir Med. 85 (2):91–99.
   PubMedGoogle Scholar
• S. Furusho, S. Myou, M. Fujimura, T. Kita, M. Yasui, K. Kasahara, S. Nakao, K. Takehara, and S. Sato. 2006. Role of intercellular adhesion molecule-1 in a murine model of toluene diisocyanate-induced asthma. Clin. Exp. Allergy 36 (10):1294–1302.
   PubMedGoogle Scholar
• V.J. Johnson, B. Yucesoy, and M.I. Luster. 2005. Prevention of IL-1 signaling attenuates airway hyperresponsiveness and inflammation in a murine model of toluene diisocyanate-induced asthma. J. Allergy Clin. Immunol. 116 (4):851–858.
   PubMedGoogle Scholar
• V.J. Johnson, B. Yucesoy, J.S. Reynolds, K. Fluharty, W. Wang, D. Richardson, and M.I. Luster. 2007. Inhalation of toluene diisocyanate vapor induces allergic rhinitis in mice. J. Immunol. 179 (3):1864–1871.
   PubMedGoogle Scholar
• S. Molet, Q. Hamid, F. Davoine, E. Nutku, R. Taha, N. Page, R. Olivenstein, J. Elias, and J. Chakir. 2001. IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J. Allergy Clin. Immunol. 108 (3):430–438.
   PubMedGoogle Scholar
• A. Lindén. 2001. Role of interleukin-17 and the neutrophil in asthma. Int. Arch. Allergy Immunol. 126 (3):179–184.
   PubMedGoogle Scholar
• M. Laan, L. Palmberg, K. Larsson, and A. Linden. 2002. Free, soluble interleukin-17 protein during severe inflammation in human airways. Eur. Respir. J. 19 (3):534–537.
   PubMedGoogle Scholar
• S. Schnyder-Candrian, D. Togbe, I. Couillin, I. Mercier, F. Brombacher, V. Quesniaux, F. Fossiez, B. Ryffel, and B. Schnyder. 2006. Interleukin-17 is a negative regulator of established allergic asthma. J. Exp. Med. 203 (12):2715–2725.
   PubMedGoogle Scholar
• A. Lindén, and M. Adachi. 2002. Neutrophilic airway inflammation and IL-17. Allergy 57 (9):769–775.
   PubMedGoogle Scholar
• M. Laan, Z.H. Cui, H. Hoshino, J. Lotvall, M. Sjostrand, D.C. Gruenert, B.E. Skoogh, and A. Linden. 1999. Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J. Immunol. 162 (4):2347–2352.
   PubMedGoogle Scholar
• H. Hoshino, M. Laan, M. Sjöstrand, J. Lotvall, B.E. Skoogh, and A. Linden. 2000. Increased elastase and myeloperoxidase activity associated with neutrophil recruitment by IL-17 in airways in vivo. J. Allergy Clin. Immunol. 105 (1 Pt 1):143–149.
   PubMedGoogle Scholar
• M. Miyamoto, O. Prause, M. Sjöstrand, M. Laan, J. Lotvall, and A. Linden. 2003. Endogenous IL-17 as a mediator of neutrophil recruitment caused by endotoxin exposure in mouse airways. J. Immunol. 170 (9):5335–5342.
   Google Scholar
• J.K. Kolls, S.T. Kanaly, and A.J. Ramsay. 2003. Interleukin-17: An emerging role in lung inflammation. Am. J. Respir. Cell Mol. Biol. 28 (1):9–11.
   PubMedGoogle Scholar
• Y. Chen, P. Thai, Y.H. Zhao, Y.S. Ho, M.M. DeSouza, and R. Wu. 2003. Stimulation of airway mucin gene expression by interleukin (IL)-17 through IL-6 paracrine/autocrine loop. J. Biol. Chem. 278 (19):17036–17043.
   PubMedGoogle Scholar
• K. Hashimoto, B.S. Graham, S.B. Ho, K.B. Adler, R.D. Collins, S.J. Olson, W. Zhou, T. Suzutani, P.W. Jones, K. Goleniewska, J.F. O'Neal, and R.S. PeeblesJr.. 2004. Respiratory syncytial virus in allergic lung inflammation increases Muc5ac and gob-5. Am. J. Respir. Crit. Care Med. 170 (3):306–312.
   PubMedGoogle Scholar